vs
Opus Genetics, Inc.（IRD）与UNITED GUARDIAN INC（UG）财务数据对比。点击上方公司名可切换其他公司
Opus Genetics, Inc.的季度营收约是UNITED GUARDIAN INC的1.3倍（$3.9M vs $3.0M），UNITED GUARDIAN INC同比增速更快（19.6% vs -10.2%），过去两年Opus Genetics, Inc.的营收复合增速更高（50.3% vs -4.6%）
Opus Genetics是一家临床阶段生物技术企业，专注开发针对遗传性视网膜疾病的靶向基因疗法，致力于为患有罕见致盲性眼部疾病的患者解决未被满足的医疗需求，核心业务为面向全球罕见病市场推进可及性治疗候选药物的研发工作。
美国守护者人寿保险公司是全球规模领先的相互制人寿保险公司之一，总部位于曼哈顿。公司在美国拥有约8000名员工，在全国70余家机构布局了超过3000名财务顾问的服务网络。2018年，该公司按营收计位列美国财富500强第239位，业内实力雄厚。
IRD vs UG — 直观对比
营收规模更大
IRD
是对方的1.3倍
$3.0M
营收增速更快
UG
高出29.7%
-10.2%
两年增速更快
IRD
近两年复合增速
-4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.9M | $3.0M |
| 净利润 | — | — |
| 毛利率 | — | 45.0% |
| 营业利润率 | — | 24.4% |
| 净利率 | — | — |
| 营收同比 | -10.2% | 19.6% |
| 净利润同比 | 53.0% | — |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IRDUG
| Q4 25 | $3.9M | $3.0M | ||
| Q3 25 | $3.1M | $2.3M | ||
| Q2 25 | $2.9M | $2.8M | ||
| Q1 25 | $4.4M | $2.5M | ||
| Q4 24 | $4.3M | $2.5M | ||
| Q3 24 | $3.9M | $3.1M | ||
| Q2 24 | $1.1M | $3.4M | ||
| Q1 24 | $1.7M | $3.3M |
净利润IRDUG
| Q4 25 | — | — | ||
| Q3 25 | $-17.5M | $268.4K | ||
| Q2 25 | $-7.4M | $626.8K | ||
| Q1 25 | $-8.2M | $560.9K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.5M | $865.5K | ||
| Q2 24 | $-7.8M | $956.2K | ||
| Q1 24 | $-7.1M | $925.4K |
毛利率IRDUG
| Q4 25 | — | 45.0% | ||
| Q3 25 | — | 42.1% | ||
| Q2 25 | — | 52.8% | ||
| Q1 25 | — | 54.7% | ||
| Q4 24 | — | 51.7% | ||
| Q3 24 | — | 54.0% | ||
| Q2 24 | — | 54.0% | ||
| Q1 24 | — | 52.2% |
营业利润率IRDUG
| Q4 25 | — | 24.4% | ||
| Q3 25 | -269.9% | 9.5% | ||
| Q2 25 | -309.0% | 24.5% | ||
| Q1 25 | -227.2% | 24.6% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | -207.1% | 31.0% | ||
| Q2 24 | -748.9% | 32.9% | ||
| Q1 24 | -450.5% | 31.5% |
净利率IRDUG
| Q4 25 | — | — | ||
| Q3 25 | -566.9% | 11.9% | ||
| Q2 25 | -257.5% | 22.1% | ||
| Q1 25 | -187.5% | 22.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -194.6% | 28.3% | ||
| Q2 24 | -698.3% | 28.2% | ||
| Q1 24 | -415.3% | 28.4% |
每股收益（稀释后）IRDUG
| Q4 25 | — | — | ||
| Q3 25 | $-0.25 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $-0.24 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.29 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.29 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $45.1M | $8.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $15.3M | $11.2M |
| 总资产 | $50.2M | $13.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IRDUG
| Q4 25 | $45.1M | $8.6M | ||
| Q3 25 | $30.8M | $8.3M | ||
| Q2 25 | $32.4M | $8.4M | ||
| Q1 25 | $41.8M | $8.1M | ||
| Q4 24 | $30.3M | $9.4M | ||
| Q3 24 | $36.6M | $9.5M | ||
| Q2 24 | $41.4M | $9.9M | ||
| Q1 24 | $47.2M | $8.6M |
股东权益IRDUG
| Q4 25 | $15.3M | $11.2M | ||
| Q3 25 | $6.0M | $10.6M | ||
| Q2 25 | $17.5M | $11.5M | ||
| Q1 25 | $5.1M | $10.8M | ||
| Q4 24 | $6.7M | $11.9M | ||
| Q3 24 | $34.3M | $11.4M | ||
| Q2 24 | $40.6M | $12.1M | ||
| Q1 24 | $46.1M | $11.2M |
总资产IRDUG
| Q4 25 | $50.2M | $13.1M | ||
| Q3 25 | $36.1M | $12.2M | ||
| Q2 25 | $38.7M | $13.4M | ||
| Q1 25 | $48.2M | $12.8M | ||
| Q4 24 | $36.9M | $13.8M | ||
| Q3 24 | $40.4M | $13.3M | ||
| Q2 24 | $44.8M | $13.8M | ||
| Q1 24 | $51.8M | $13.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-35.3M | $330.5K |
| 自由现金流经营现金流 - 资本支出 | — | $308.0K |
| 自由现金流率自由现金流/营收 | — | 10.4% |
| 资本支出强度资本支出/营收 | — | 0.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $1.9M |
8季度趋势，按日历期对齐
经营现金流IRDUG
| Q4 25 | $-35.3M | $330.5K | ||
| Q3 25 | $-6.2M | $1.0M | ||
| Q2 25 | $-10.3M | $303.2K | ||
| Q1 25 | $-9.0M | $322.1K | ||
| Q4 24 | $-25.6M | $269.3K | ||
| Q3 24 | $-5.1M | $1.2M | ||
| Q2 24 | $-7.3M | $1.3M | ||
| Q1 24 | $-5.7M | $644.1K |
自由现金流IRDUG
| Q4 25 | — | $308.0K | ||
| Q3 25 | — | $995.8K | ||
| Q2 25 | — | $285.6K | ||
| Q1 25 | — | $318.5K | ||
| Q4 24 | — | $-45.9K | ||
| Q3 24 | — | $1.2M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $622.2K |
自由现金流率IRDUG
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | — | 10.1% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | -1.9% | ||
| Q3 24 | — | 39.2% | ||
| Q2 24 | — | 37.1% | ||
| Q1 24 | — | 19.1% |
资本支出强度IRDUG
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 0.7% |
现金转化率IRDUG
| Q4 25 | — | — | ||
| Q3 25 | — | 3.77× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 0.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | 1.38× | ||
| Q1 24 | — | 0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IRD
暂无分部数据
UG
| Pharmaceuticals | $1.6M | 53% |
| Other | $1.4M | 47% |
